Innovative Approach to a Life-Threatening Disorder
Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) is a severe autoimmune condition where autoantibodies target ADAMTS13, leading to unchecked formation of microthrombi. Despite existing therapies, up to 15% of patients experience relapses post-rituximab treatment. This study introduces a novel strategy using reverse Chimeric Antigen Receptor (CAR) T cells to address these challenges.
